Background
==========

Recurrent pregnancy loss (RPL) is a common clinical problem that may occur during pregnancy. About 15% of clinically recognized pregnancies could suffer from RPL before the 20^th^ week of gestation, with no known cause \[[@b1-medscimonit-21-1051]\]. The pathogenesis of RPL remains unknown in many patients, and approximately 55% of patients are suspected to have thrombophilic defects \[[@b2-medscimonit-21-1051]\].

Thrombophilia is a common cause of RPL and is found in 40--50% of cases \[[@b3-medscimonit-21-1051]\]. Laude et al. found that levels of circulating procoagulant microparticles were higher in women with RPL when compared with controls \[[@b4-medscimonit-21-1051]\]. Thrombophilia might cause a syncytiotrophoblast invasion of the maternal blood vessels, which could lead to the formation of microthrombosis at the site of implantation and result in RPL and implantation failure \[[@b5-medscimonit-21-1051]\].

Plasminogen activator inhibitor-1 (PAI-1) is the urinary plasminogen activator and principal inhibitor of tissue. The main function of PAI-1 is converting plasminogen to the proteolytic enzyme plasmin \[[@b6-medscimonit-21-1051]\]. Sun and colleagues found that PAI-1 4G/5G polymorphism was significant positive explanatory variable for polycystic ovary syndrome (PCOS) patients with spontaneous abortions \[[@b7-medscimonit-21-1051]\]. In addition, PAI-1 4G/5G polymorphism was associated with increased PAI-1 concentrations and hypofibrinolysis and contributed to early pregnancy loss \[[@b7-medscimonit-21-1051]\]. Many studies assessed the association between PAI-1 4G/5G polymorphism and RPL risk \[[@b8-medscimonit-21-1051]--[@b29-medscimonit-21-1051]\]. However, the result was still uncertain. A meta-analysis found that PAI-1 4G/5G polymorphism did not increase the risk of RPL. However, recent studies did not confirm this result \[[@b24-medscimonit-21-1051],[@b25-medscimonit-21-1051],[@b27-medscimonit-21-1051]\]. Therefore, we conducted this meta-analysis to investigate the association between PAI-1 4G/5G polymorphism and RPL risk.

Material and Methods
====================

Publication search
------------------

Relevant studies were searched for in PubMed, Web of Science, Embase, and Cochrane Library. The following terms and strategies were used for the search: ("Plasminogen activator inhibitor-1" OR "PAI-1") AND ("single nucleotide polymorphism" OR "SNP" OR "genetic variation" OR "genetic polymorphism") AND ("Recurrent pregnancy loss" OR "RPL"). To avoid possible missing of qualified trails, introduction and reference list of eligible trails identified through primary search were screened manually. No language restriction was applied when searching.

Inclusion and exclusion criteria
--------------------------------

The following criteria were used to screen eligible studies for this meta-analysis: (1) a case**--**control study or cohort study that studied the association between PAI-1 4G/5G polymorphism and RPL risk; and (2) sufficient data were available for calculation of allele/genotype frequency. Only studies meeting both these criteria were included for analysis.

Data extraction
---------------

Two authors extracted the data independently. These data included: the first author, year, ethnicity, genotype distribution, and sample size. Disagreement in data extraction was resolved by group discussion by referring to original studies with a third reviewer.

Statistical analysis
--------------------

The odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated to assess the association between PAI-1 4G/5G polymorphism and RPL risk. The recessive genetic model (4G/4G *vs.* 4G/5G+5G/5G) was chosen, because PAI-1 4G/4G genotype was significantly associated with increased PAI-1 production. The significance of pooled estimates was assessed with Z test. Hardy-Weinberg equilibrium (HWE) of genotype frequency in the control group was assessed by chi-square test. Between-studies heterogeneity was assessed by the chi-square-based Q test and *I*^2^. *P*\<0.1 or *I*^2^\>50% was considered as significant heterogeneity. If no significant heterogeneity was observed, fixed-effects model with Mantel**-**Haenszel method was used to make estimates. However, if significant heterogeneity observed, the sources of heterogeneity would be further analyzed by Galbraith plots. If there were no significant clinical or methodological differences in trails, the random effects model based on DerSimonian-Laird method was be used. Subgroup analysis was performed based on ethnicity of participants recruited in each study. A cumulative meta-analysis was conducted. Sensitivity analysis by another model, HWE, and sample size were also conducted. Publication bias was tested using Begg's test and funnel plot (*P*\<0.05 was considered as significant). Statistical analysis was conducted using Stata software 11.0 (StataCorp, College Station, Texas, USA).

Results
=======

Study characteristics
---------------------

After searching and screening with preset criteria, a total of 22 studies with 4306 cases and 3076 controls were included for this meta-analysis. Four studies were conducted in Asians and 18 in Caucasians. The characteristics and the HWE results of the included studies are listed in [Table 1](#t1-medscimonit-21-1051){ref-type="table"}. Four studies were not in HWE.

Meta-analysis results
---------------------

As shown in [Figure 1](#f1-medscimonit-21-1051){ref-type="fig"}, we found that PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk (OR=1.89; 95% CI 1.34--2.67; *P*=0.0003). In the subgroup analysis by race, PAI-1 4G/5G polymorphism was significantly associated with an increased RPL risk in Caucasians (OR=2.23; 95% CI 1.44--3.46; *P*=0.0003). However, no significant association was observed in Asians (OR=1.47; 95% CI 0.84--2.59; *P*=0.18). Results of the meta-analysis are listed in [Table 2](#t2-medscimonit-21-1051){ref-type="table"}. In the sensitivity analysis, when the fixed-effects model was used, the result was still positive (OR=1.87; 95% CI 1.64--2.13; *P*\<0.00001). When the studies without HWE were excluded, the result was not changed (OR=1.56; 95% CI 1.12--2.19; *P*=0.009). Furthermore, when the studies with small sample size were excluded, the result was also not changed (OR=1.98; 95% CI 1.25--3.13; *P*=0.004). The results of sensitivity analysis are listed in [Table 3](#t3-medscimonit-21-1051){ref-type="table"}.

Results from the cumulative meta-analysis suggest that the evidence was consistent over time ([Figure 2](#f2-medscimonit-21-1051){ref-type="fig"}), indicating that the results of this meta-analysis are robust. Significant heterogeneity (*I*^2^=81%) was detected in the recessive genetic model. Thus, we used the Galbraith plot to explore the source of the heterogeneity. As shown in [Figure 3](#f3-medscimonit-21-1051){ref-type="fig"}, 10 studies were considered as outliers. When these studies were excluded, the heterogeneity was decreased. No obvious heterogeneity among the remaining studies could be found (*I*^2^=0%). Furthermore, the result was significant (OR=1.48, 95% CI 1.22--1.79, *P*\<0.0001). No significant publication bias was found by Begg's funnel plot ([Figure 4](#f4-medscimonit-21-1051){ref-type="fig"}) and Egger's test (*P*=0.313).

Discussion
==========

Our previous meta-analysis investigated the association between PAI-1 4G/5G polymorphism and RPL risk \[[@b30-medscimonit-21-1051]\]. However, that meta-analysis did not find a positive association between PAI-1 4G/5G polymorphism and risk of RPL. Several new studies have been published since then. Thus, we did a new meta-analysis. When these new studies were included, we found that PAI-1 4G/5G polymorphism was significantly associated with risk of RPL, indicating that PAI-1 4G/5G polymorphism carriers might have increased RPL risk. In the subgroup analysis based on race, PAI-1 4G/5G polymorphism showed increased RPL risk in Caucasians. However, no positive association was found in Asians. Ethnic differences can occur in genotype frequencies, which might account for the different results. In addition, there were only four studies with Asians. More studies with Asian populations are needed to validate this result. We then did cumulative meta-analysis. We found that the result from our meta-analysis was stable. In the sensitivity analyses, we also found the results were not altered, indicating this meta-analysis was robust.

In human and animal models, PAI-1 was involved not only in fibrinolysis regulation, but also in extracellular proteolytic processes during ovulation, ovarian follicle growth, and embryo implantation \[[@b31-medscimonit-21-1051],[@b32-medscimonit-21-1051]\]. Much evidence has suggested that abnormal levels of PAI-1 significantly increase miscarriage and complicated pregnancy rates \[[@b33-medscimonit-21-1051]\]. Additionally, Glueck et al. suggested that PAI activity was a significant positive explanatory variable for the number of miscarriages \[[@b34-medscimonit-21-1051]\]. Furthermore, Glueck et al. found that administration of metformin throughout pregnancy in women with PCOS reduced the risk of first-trimester spontaneous abortion \[[@b35-medscimonit-21-1051]\]. Palomba and coworkers also confirmed that metformin reduced PAI-1 activity in women with PCOS and abortion risk \[[@b36-medscimonit-21-1051]\]. Therefore, it might be possible that increased PAI-1 associated with high RPL risk and PAI-1 4G/5G polymorphism might influence RPL risk.

There were some limitations in this meta-analysis. First, lack of the original data limited the evaluation of gene-gene and gene-environment interactions. Second, Dawson et al. indicated that PAI-1 level was not only changed by PAI- 1 4G/5G polymorphism, but also by concentration of blood sugar, insulin, and triglycerides \[[@b37-medscimonit-21-1051]\]. However, we did not adjust these factors in this meta-analysis due to lack of original data. Third, the studies included in our meta-analysis were small. Thus our meta-analysis had little statistical power to assess the association between the PAI-1 4G/5G polymorphism and RPL risk.

Conclusions
===========

The results of this meta-analysis suggest that PAI-1 4G/5G polymorphism might be associated with RPL development in Caucasians. Large-scale studies are necessary to validate this result.
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###### 

Characteristics of the studies included in this meta-analysis.

                         Year   Ethnicity   Case   Control   Case   Control   HWE                     
  ---------------------- ------ ----------- ------ --------- ------ --------- ----- ----- ----- ----- -----
  Wolf                   2003   Caucasian   49     102       17     25        7     32    50    20    Yes
  Buchholz               2003   Caucasian   184    127       72     75        37    41    58    28    Yes
  Dossenbach-Glaninger   2003   Caucasian   49     48        12     28        9     8     25    16    Yes
  Guan                   2005   Asian       127    117       58     52        17    20    59    38    Yes
  Coulam                 2006   Caucasian   150    20        11     117       22    2     13    5     Yes
  Coulam                 2008   Caucasian   550    41        39     396       115   6     22    13    Yes
  Goodman                2009   Caucasian   120    84        38     57        25    23    48    13    Yes
  Al Sallout             2010   Caucasian   100    100       16     44        40    16    48    36    Yes
  Ivanov                 2010   Caucasian   110    97        46     44        20    26    45    26    Yes
  Ivanov                 2011   Caucasian   52     125       14     23        15    26    45    26    Yes
  Aarabi                 2011   Caucasian   63     114       19     30        14    25    47    22    Yes
  Jeddi-Tehrani          2011   Caucasian   100    100       9      31        60    1     27    72    Yes
  Idali                  2012   Caucasian   106    100       17     53        35    1     27    72    Yes
  Torabi                 2012   Caucasian   100    100       9      31        60    1     27    72    Yes
  Ozdemir                2012   Caucasian   543    327       121    331       91    10    62    34    No
  Parveen                2013   Asian       200    300       45     100       55    74    131   95    No
  Magdoud                2013   Caucasian   304    371       37     128       139   10    104   257   Yes
  Subrt                  2013   Caucasian   157    74        59     75        23    10    54    10    No
  Jeon                   2014   Asian       308    227       129    132       47    71    117   39    Yes
  Khosravi               2014   Caucasian   595    100       122    288       184   1     27    72    Yes
  Kim                    2014   Asian       227    304       73     123       31    102   154   48    Yes
  Lino                   2014   Caucasian   112    98        12     57        37    16    40    42    Yes

HWE -- Hardy-Weinberg equilibrium.

###### 

Results of meta-analysis.

  Comparison                Subgroup    No. studies   OR (95% CI)         P Value   *I*^2^ (%)
  ------------------------- ----------- ------------- ------------------- --------- ------------
  4G/4G *vs.* 4G/5G+5G/5G   Overall     22            1.89 (1.34--2.67)   0.0003    81
  4G/4G *vs.* 4G/5G+5G/5G   Asian       4             1.47 (0.84--2.59)   0.18      86
  4G/4G *vs.* 4G/5G+5G/5G   Caucasian   18            2.23 (1.44--3.46)   0.0003    79

###### 

Results of sensitivity analyses.

  Comparison                Subgroup             No. studies   OR (95% CI)         P Value     *I*^2^ (%)
  ------------------------- -------------------- ------------- ------------------- ----------- ------------
  4G/4G *vs.* 4G/5G+5G/5G   Fixed-effect model   22            1.84 (1.61--2.09)   \<0.00001   81
  4G/4G *vs.* 4G/5G+5G/5G   HWE                  19            1.56 (1.12--2.19)   0.009       67
  4G/4G *vs.* 4G/5G+5G/5G   n\<200               16            1.98 (1.25--3.13)   0.004       84
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